Inhibition of Angiotensin Converting Enzyme by CV-3317 a Non-Sulfhydryl Compound
スポンサーリンク
概要
- 論文の詳細を見る
N-[N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-N-(indan-2-yl)glycine hydrochloride (CV-3317) and its de-esterified products, CV-3317-COOH and CV-3317-(5-OH)-COOH, inhibited rabbit lung angiotensin converting enzyme (ACE) with the IC50s of 1.2×10<SUP>-7</SUP>, 4.0×10<SUP>-8</SUP> and 4.0×10<SUP>-8</SUP> M, respectively, angiotensin I(A-I)-induced vasoconstriction of the rat aorta (IC50: 2.6×10<SUP>-7</SUP>, 2.6×10<SUP>-8</SUP> and 5.4×10<SUP>-8</SUP> M, respectively), and A-I-induced pressor response of the rat kidney (IC50: 3.9×10<SUP>-7</SUP>, 3.5×10<SUP>-8</SUP> and 2.8×10<SUP>-8</SUP> M, respectively). In these 3 experiments, both de-esterified products were 4 to 14 times more potent than captopril. In rats, CV-3317 (0.0138 to 138 μmol/kg, p.o.) inhibited plasma and lung ACEs, and the effects at a dose of 0.46 μmol/kg lasted more than 8 hr. CV-331 7 inhibited the A-I-induced pressor action in rats (0.138 to 13.8 μmol/kg, p.o. or 0.046 to 0.138 μmol/kg, i.v.) and dogs (0.46 to 4.6 μmol/kg, p.o.) in a dose-related manner. CV-3317 was more potent and longer acting than captopril in these in vivo ACE inhibitions. CV-3317 augmented bradykinin-induced hypotension (dogs) and contraction of the ileum (guinea pigs) less potently than captopril. In spontaneously hypertensive rats (SH R), CV-3317 (3 mg/kg, p.o.) markedly inhibited plasma and tissue (aorta, kidney, lung and brain) ACEs; and when administered daily for 2 weeks, it inhibited the plasma, aorta, kidney and lung ACEs; in particular, it markedly inhibited the aortic ACE. Captopril (30 mg/kg, p.o.) markedly inhibited tissue ACEs and slightly plasma ACE, but its inhibitory effects on tissue ACEs, except for the aorta, were unclear by repeated closings and its effect on plasma ACE was rather enhanced. Thus, the inhibition of vascular ACE may be particularly important for the antihypertensive effect of the ACE inhibitors, includin CV-3317, in SHR.
著者
-
KIKUCHI Shintaro
Central Research Division, Takeda Chemical Industries, Ltd.
-
NISHIKAWA Kohei
Biological Research Laboratories, Central Research Division, Takeda Chemical Industries, Ltd.
-
INADA Yoshiyuki
Biology Laboratories, Central Research Division, Takeda Chemical Industries, Ltd.
-
TERASHITA Zen-ichi
Biology Laboratories, Takeda Chemical Industries, Ltd.
-
IMURA Yoshimi
Biology Laboratories, Takeda Chemical Industries, Ltd.
-
TANABE Masao
Biology Laboratories, Central Research Division, Takeda Chemical Industries Ltd.
関連論文
- Inhibition of Angiotensin Converting Enzyme by CV-3317 a Non-Sulfhydryl Compound
- EFFECTS OF ARACHIDONIC ACID AND BRADYKININ ON THE CORONARY FLOW, RELEASE OF PGI2 AND CARDIAC FUNCTIONS IN THE PERFUSED GUINEA-PIG HEART
- INVOLVEMENT OF ADRENERGIC MECHANISM IN THE DIURETIC ACTION OF o-CHLOROBENZYL METHYL SULFOXIDE (DS-30) IN THE RAT
- Antagonistic action of AA-2414 on thromboxane A2/prostaglandin endoperoxide receptor in platelets and blood vessels.
- (R)-3-((S)-1-carboxy-5-(4-piperidyl)pentyl)amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetic acid (CV-5975): A new potent and long-lasting inhibitor of angiotensin converting enzyme.
- Calcium channel blocking action of franidipine hydrochloride (CV-40932HCl) in vitro and in vivo.
- Antihypertensive action of a new angiotensin converting enzyme inhibitor, (R)-3-((S)-1-carboxy-5-(4-piperidyl)pentyl)amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepine-5-acetic acid (CV-5975), in various hypertensive models.
- Antihypertensive action of a non-sulfhydryl angiotensin converting enzyme inhibitor (CV-3317) in various hypertensive models.
- Effects of CV-3611, a new free radical scavenger, on ischemic heart failure in conscious beagle dogs.